
Sign up to save your podcasts
Or


In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
We also cover
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.
By Sasha High4.9
3434 ratings
In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
We also cover
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.

577 Listeners

2,114 Listeners

333 Listeners

609 Listeners

47 Listeners

1,646 Listeners

386 Listeners

245 Listeners

217 Listeners

16 Listeners

364 Listeners

35 Listeners

167 Listeners

14 Listeners

42 Listeners